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Abstract
Background: Value assessment of vaccination programs against serogroup B invasive meningococcal disease (IMD) is
on the agenda of public health authorities. Current evidence on the burden due to IMD is unfit for pinning down the
nature and magnitude of the full social and economic costs of IMD for two reasons. First, the concepts and
components that need to be studied are not agreed, and second, measures of the concepts that have been studied
are weak and inconsistent. Thus, the economic evaluation of the available serogroup B meningococcal (MenB) vaccines
is difficult. The aims of this DELPHI study are to: (1) agree on the concepts and components determining the burden of
MenB diseases that need to be studied; and (2) seek consensus on appropriate methods and study designs to measure
quality of life (QoL) associated with MenB induced long-term sequelae in future studies.
Methods: We designed a DELPHI questionnaire based on the findings of a recent systematic review on the QoL
associated with IMD-induced long-term sequelae, and iteratively interviewed a panel of international experts, including
physicians, health economists, and patient representatives. Experts were provided with a controlled feedback based on
the results of the previous round.
Results: Experts reached consensus on all questions after two DELPHI rounds. Major gaps in the literature relate (i) to
the classification of sequelae, which allows differentiation of severity levels, (ii) to the choice of QoL measures, and (iii)
to appropriate data sources to examine long-term changes and deficits in patients’ QoL.
Conclusions: Better conceptualisation of the structure of IMD-specific sequelae and of how their diverse forms of severity
might impact the QoL of survivors of IMD as well as their family network and care-providers is needed to generate
relevant, reliable and generalisable data on QoL in the future. The results of this DELPHI panel provide useful guidance on
how to choose the study design, target population and appropriate QoL measures for future research and hence, help
promote the appropriateness and consistency in study methodology and sample characteristics.
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Focus on the patient
What is the context?
- Invasive meningococcal disease (IMD) has the highest
incidence rate in young children. In the short term, IMD
causes meningitis and/or sepsis. In the long term, IMD
survivors can suffer from sequelae of various types and
severity levels.
- Current available evidence does not fully capture the
burden of long-term sequelae in IMD survivors and
their societal consequences, mainly due to gaps and
weaknesses in methods of assessment.
What is new?
- A DELPHI questionnaire was designed and submitted
to a board of international experts, including medical
doctors, health economists and patient representatives.
- The experts reached consensus on optimal and rec-
ommended sequelae classification, study sample charac-
teristics, study design, and quality of life measurement
instruments and indicators.
What is the impact?
- The experts’ recommendations should help harmonise
methodologies to assess the quality of life of IMD survi-
vors (as well as their close family members and carers)
with long-term sequelae in future studies so that more
consistent data can be meaningfully compared, com-
bined, and utilised.
- High-quality and relevant data are a prerequisite to
support evidence-based public health decision making.
Background
Invasive meningococcal disease (IMD) potentially leads
after an acute phase to serious long-term sequelae and
complications and possibly premature death, thus imposing
a high burden onto the patients and their carers [1–3]. The
disease is caused by the bacterium Neisseria meningitidis
and predominantly affects infants and young children [4, 5].
Main clinical presentations of IMD are sepsis and/or men-
ingitis. Six serogroups A, B, C, W, X and Y primarily cause
IMD [5, 6]. Although IMD occurs globally, the distribution
of serogroups varies across regions. While serogroups B, C
and Y are the leading cause of IMD in Europe and other re-
gions of higher-income, such as North America, serogroups
A, C, W and X are dominant in the meningitis belt of
sub-Saharan Africa. However, serogroup W is now also a
leading cause of IMD in some European countries such as
the United Kingdom or the Netherlands [7–11].
The availability of vaccines and the implementation of
universal mass vaccination (UMV) programs for children
decreased the incidence of serogroup C in Europe [4, 11].
Decision-making processes on whether to recommend
serogroup B meningococcal (MenB) UMV in European
countries are concluded or ongoing [12]. Of the reported
IMD cases in Europe in 2016, the majority (54%) was at-
tributable to serogroup B, whereas C accounted for 16%.
While serogroup B is responsible for most cases of IMD,
especially in children under the age of five, serogroups C,
Y and W are predominantly responsible for IMD cases in
older age groups [4]. Of note, the clinical presentation of
IMD caused by serogroup B is not significantly different
from that of other serogroups [13, 14]. Further, associa-
tions between both the chance of occurrence and severity
of sequelae and serogroups are inconclusive due to low
case numbers [13, 15, 16].
Although the incidence of MenB-related IMD is rela-
tively low, the disease has high social and economic costs
[17, 18]. However, current evidence on the disease burden
does a poor job of pinning down the nature and magni-
tude of the full costs of IMD for two reasons. First, the
concepts and components that need to be studied are not
agreed upon, and second, measures of the concepts that
have been studied are weak and inconsistent. Hence, a
proper translation of the burden on an outcome measure
that can be applied for economic evaluation is lacking.
Olbrich et al. (2018) argue that the quality of life (QoL) loss
caused by IMD cannot precisely be quantified and assessed
since published studies are highly heterogeneous regarding
the study design and QoL measurement. This is due to a lack
of QoL measurements which differentiate between survivors
of IMD with and without sequelae, or QoL measurements
specific to types and severity levels of sequelae associated
with IMD [16]. Gasparini et al. highlight the importance of
accurately estimating the incidence of disease and its conse-
quences, i.e. the type and probability of being left with certain
sequelae and the corresponding disutility, to correctly ac-
count for the decrease in QoL in IMD patients [19].
Moreover, the measurement of QoL in infants and chil-
dren is methodologically more challenging than in adults,
as shown by Herdman et al. (2016) for IMD cases [20].
Additionally, the perception of health and impairments due
to illness might change when patients age and reach adult-
hood, implying further requirements when QoL is mea-
sured along the transition to adulthood. This relates
especially to the choice of an appropriate valuation tech-
nique, the resulting value sets or the necessity to change
the instrument [21]. The impact of the various forms of se-
quelae on the QoL of IMD survivors remains unclear and
seems underestimated [8, 16]. Not only does IMD have a
direct impact on the patients, it also has indirect conse-
quences for carers, family members and for the society.
These wider health effects might also need to be taken into
account for economic evaluation [2, 3, 19].
The aims of this DELPHI study were to:
(1) agree on the concepts and components
determining the burden of MenB diseases that
need to be studied; and
Marten et al. Health and Quality of Life Outcomes           (2019) 17:87 Page 2 of 9
(2) seek consensus on appropriate methods and study
designs to measure the QoL associated with MenB-
induced long-term sequelae in future studies.
Methods
We used a DELPHI panel approach to find consensus
on data gaps and the most appropriate study design to
measure the QoL associated with IMD sequelae. The
purpose of a normative DELPHI approach is to identify
and answer questions of what should be and what is de-
sirable in the future, rather than to assess the current,
highly imperfect literature [22]. The conventional DEL-
PHI aims at gathering expert opinion and studying its
evolution across iterative rounds of discussion, typically
gravitating toward a consensus-based group opinion
among the participating experts [23].
The iterative process inherent in the DELPHI tech-
nique enables the evolution of the experts’ opinion on
the specified research topic, where, due to the controlled
feedback, experts re-consider and re-assess their per-
spective by including broader views and additional infor-
mation provided by the other participating experts [24,
25]. Furthermore, the DELPHI allows the application of
both qualitative and quantitative measures. The former
strengthens the in-depth understanding of the expert’s
answers, whereas the latter provides a ground for statis-
tical analyses of the data to reach a consensus [26, 27].
The expert panel
In accordance with the expert definitions provided by
Keeney et al. (2001), we invited specialists with experi-
ence in measuring QoL, especially that associated with
meningococcal long-term sequelae [28]. The expert
panel comprised epidemiologists, clinicians, paediatri-
cians, psychologists, patient representatives as well as
health economists. Each of the experts has profound ex-
perience with study designs, data collection, or clinical
experience in the treatment of IMD or in the measure-
ment of QoL, especially in children and adolescents.
Additionally, we selected experts to cover the patient’s
perspective as well as clinical aspects specific to IMD.
Experts were from the UK, USA, Germany, Australia,
the Netherlands, Canada, Brazil and Norway in order to
cover the international interest to patients, public health
authorities and clinicians. Ultimately, 16 experts partici-
pated in the DELPHI panel ensuring a broad and appro-
priate pooling of expert opinions [25, 27].
The DELPHI process
The first DELPHI round was informed by a systematic lit-
erature review. The initial questionnaire provided to ex-
perts covered the relevant gaps identified in the recent
review by Olbrich et al. [16] and comprised 11 questions
(Additional file 1). Of those, five questions were
formulated as choice tasks, where the experts had to
choose one of the pre-defined items. Four ranking tasks
asked the respondents to rank n given items numerically,
where 1 represents the most important and n the least im-
portant option. Hence, increasing rank numbers corres-
pond to less preferred answers [29]. Two qualitative
questions were included to further explore the experts’
opinions. The choice and ranking tasks gave experts the
opportunity to explain their answer or to supplement the
list of items within each task.
Along with the initial questionnaire, experts received
in March 2017 instructions, a glossary, and a detailed
introduction providing a summary of the results from
the systematic literature review to ensure proper under-
standing of the questionnaire. The experts answered the
first round questionnaire individually (via e-mail) and
anonymously not knowing of the other experts, which
Dalkey et al. (1962) recommend as a strategy to minim-
ise group-based interactions between experts [23].
The second round of the DELPHI panel was held in a
presence meeting in March 2017 enabling the provision
of a summary of the first-round responses with a subse-
quent discussion giving each expert the opportunity to
voice or revise his/her previous answers. Subsequently,
an adapted questionnaire with eight questions was given
to the experts. For the second round, the two qualitative
questions 4 and 11 were dropped for parsimony, since
potential answers were collected within the first round
or recorded and debated during the discussion. We fur-
ther dropped question 6, which was unanimously an-
swered during the first round and, hence, a consensus
on that specific question was already reached. This sec-
ond questionnaire also provided feedback from the first
round. For the choice tasks the answer distribution was
given. Regarding the ranking tasks, experts were pro-
vided with the group ranking derived from the rank sum
of each item per question.
Analysis, convergence and consensus
All closed questions had to be either ranked or selected
by the experts. Descriptive analyses of the results of the
ranking and choice tasks were undertaken. We aggre-
gated the individual ranks into a group ranking by calcu-
lating the rank sums; since lower numbers represent a
better rank, the items with the lowest rank sum will be
considered as the preferred options. The minimum and
maximum rank, the mean rank, and the mode of each
item were analysed (not reported). Additionally, we eval-
uated the results from the choice tasks with the help of
histograms inspecting the frequency distribution of the
items for each question.
Convergence was measured using Kendall’s W, a
non-parametric test assessing the level of agreement in
an expert group. The test statistic ranges from 0 to 1,
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where 0 means no agreement and 1 represents full
agreement among the experts [30]. The convergence in
the choice tasks was assessed by comparing the share of
experts selecting a given answer category across rounds.
Hence, if the experts’ opinion converges towards a mu-
tually accepted option, the share of experts choosing this
particular option should increase while the shares for
the remaining items decrease.
A consensus was defined differently for rank and choice
questions. In terms of the choice tasks, a consensus was
reached when 2/3 of the experts agreed on addressing an
issue in a certain way and no veto was raised [31]. A veto
could be raised due to ethical, legal, or methodological
concerns. In the ranking exercises, we considered the top
3 items per question as the consensus solution, if the 3
corresponding items remained constant across the two
rounds. Further, we required Kendall’s W to increase from
the first to the second round, implying an increased agree-
ment among the raters [30]. In terms of Kendall’s W, the
level of consensus was defined as strong for W > = 0.7,
moderate for W = 0.5 and weak for W < 0.3 [29].
Results
We present key results of the two DELPHI rounds con-
ducted in this study from 5 questions. The first-round
questionnaire can be accessed in the Additional file 1.
We achieved an expert consensus on all ranking and
choice tasks. From the first to the second round of rank-
ing tasks we observed Kendall’s W to be monotonically
increasing (Tables 2, 3 and 4), resulting in moderate to
strong levels of agreement after the second round. For
all but one of the choice tasks a 2/3 majority was
achieved after the second round.
Question 1 – conceptualisation of sequelae
Table 1 tabulates responses to question 1. For the three
tier options presented, the first-round votes showed a
slight preference for tier three (with 8 votes) compared
to tier two with 6 votes, and tier three with 2 votes. At
the end of the second round, 13 out of 14 experts voted
for tier three indicating an agreement level of almost
93%. During the process, the experts’ comments empha-
sized the importance of
 a conceptual model of sequelae, with
○ a detailed classification of sequelae,
○ allowing to distinguish the severity of sequelae,
○ reflecting the impact of multiple simultaneous
sequelae
 putting in place the processes for measuring sequelae.
Experts also stated that the sought-after concept of seque-
lae must be meaningfully measurable and therefore requires
a sufficiently large number of patients for each category.
Question 2 – target population for QoL measurement
The results of this ranking task showed good ability to
distinguish among the options (Tables 2 and 3). Assum-
ing that all options were equally important for the dis-
ease burden assessment, the rank sums of all options
would be equally high. However, the difference in the
rank sums between the target groups being deemed the
most and least important by the experts for a full disease
burden assessment ranged from 50 to 62 points in the
two younger age groups and from 65 to 72 points in the
adult group. Thus, indicating that the experts had a clear
preference order over the importance of the individual
target groups. The first-round votes showed a strong
preference, in both minor as well as severe sequelae and
in all age groups, for patients with an IMD history. Fur-
ther, the closest carer (i.e. parents, spouse or siblings)
were important when assessing the impact of IMD on
QoL. This pattern was confirmed in the second round.
The preference for the response options “patient”, “par-
ents”, “siblings” and “spouse” got stronger, as the rank
sums decreased. The experts agreed that besides meas-
uring the QoL losses in patients, negative spillover ef-
fects onto the patients’ parents and siblings should also
be considered mainly for the two younger age groups
(0–5 and 6–18 year olds), whereas in the adult group (>
18 years) the spouse was more important relative to the
other groups for the assessment of QoL losses. This ob-
servation is confirmed by the monotonic increase in
Kendall’s W indicating a strong level of agreement with
W ranging from 0.73–0.77 for the two younger age
groups, whereas the agreement remains at a moderate
level in the adult age groups (Tables 2 and 3).
Question 7 – viable measures for QoL assessment
The first-round votes resulted in heterogeneous responses
and low agreement (Kendall’s W < 0.3) on using any of the
presented methods to measure the QoL for the two IMD
patient age groups (Table 4). However, there was a slight
preference for using established measures for both age
groups (8–18 years and > 18 years), i.e. existing generic or
disease-specific instruments as well as the visual analogue
scale. During the second round (Table 4), the preference
for these measures became stronger. By contrast, methods
of direct preference elicitation, where respondents are
asked to attach a value to their health state directly, were
ranked lowest independently of the patient’s age, except for
Table 1 First and second round responses to Question 1
Tier Frequency Frequency
1st round 2nd round
3rd tier 8 13
2nd tier 6 1
1st tier 2 0
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those using a visual analogue scale. The agreement level on
the ranking of the alternatives reached a moderate level
after the second round. During the discussion, experts
raised requirements for the questionnaire. It should be
cross-country validated, age adequate, and cross-study
comparable. Consequently, it was concluded that either of
the first to third ranked measures is a sensible choice. Al-
ternatively, developing a disease-specific and age adequate
instrument should be considered.
Question 9 – demand for more longitudinal data
Figure 1 summarises the responses given during both
rounds. During the first DELPHI round, 9 experts voted for
a longitudinal design, whereas 7 experts chose a cross-sec-
tional design. There was also agreement that 2–3 repetitions
of the survey were sufficient, and there was almost equal
opinion on the follow-up period: 3–20 years with a mode of
5 years. Two experts noted that cross-sectional surveys
might be sufficient given that the conduct of long-term lon-
gitudinal studies is difficult and costly. Nonetheless, they
preferred a longitudinal design. The distinction between
studies using the same or different sample(s) for a repeated
cross-sectional study was not considered during the 1st
round. Given the preference for a longitudinal study design,
this option was made available to address this characteristic.
The results from the second round show a shift from a lon-
gitudinal study to a cross-sectional design, as all participants
voted for a cross-sectional design. Finally, the experts agreed
that the minimum requirement for a disease burden study
would be a single cross-sectional design (67% of experts).
They also indicated that a repeated cross-sectional study
would be preferred.
Question 10 – choice of an observational study design
During the first round, 4 experts selected Cohort study, 6
selected Case-control study, and 6 selected Cross-sec-
tional study. It should be noted that the case-control de-
sign was defined as a retrospective comparison of health
status between patients with a history of IMD (cases) and
no such history (controls). Thus, after the first round, a
tendency towards pragmatic and less costly study designs
was observed. In the meeting prior to the second round,
this question was discussed more in depth and in the light
of the preceding question 9. In the second round, eight
experts voted for a cross-sectional design, while 6 experts
preferred a case-control study and 2 experts chose the co-
hort study design, hence with 50% of the respondents
Table 2 Ranking results from Question 2 – light forms of sequelae
Age group 0–5 years 6–18 years > 18 years
Group Rank sum (group ranking) Rank sum (group ranking) Rank sum (group ranking)
First round Second round First round Second round First round Second round
Patients with an IMD history 22 (1) 15 (1) 16 (1) 14 (1) 16 (1) 14 (1)
Spouse n/a n/a n/a n/a 46 (2) 37 (2)
Parents 28 (2) 27 (2) 31 (2) 28 (2) 48 (3) 39 (3)
Siblings 50 (3) 43 (3) 51 (3) 43 (3) 63 (4) 55 (4)
Peers (e.g. class mates, friends) 69 (4) 60 (4) 63 (4) 57 (4) 66 (5) 60 (5)
Teachers 71 (5) 66 (5) 69 (5) 68 (5) 88 (6) 78 (6)
Health Care Professionals 72 (6) 71 (6) 78 (6) 72 (6) 88 (6) 79 (7)
Kendall’s W 0.56 0.74 0.63 0.77 0.54 0.60
Table 3 Ranking results from Question 2 – severe forms of sequelae
Age group 0–5 years 6–18 years > 18 years
Group Rank sum (group ranking) Rank sum (group ranking) Rank sum (group ranking)
First round Second round First round Second round First round Second round
Patients with an IMD history 22 (1) 14 (1) 17 (1) 14 (1) 16 (1) 14 (1)
Spouse n/a n/a n/a n/a 42 (2) 37 (2)
Parents 27 (2) 28 (2) 29 (2) 28 (2) 44 (3) 38 (3)
Siblings 49 (3) 42 (3) 49 (3) 42 (3) 62 (4) 55 (4)
Peers (e.g. class mates, friends) 68 (4) 60 (4) 65 (4) 57 (4) 70 (5) 60 (5)
Teachers 72 (5) 64 (5) 67 (5) 66 (5) 86 (6) 79 (6)
Health Care Professionals 73 (6) 71 (6) 78 (6) 72 (6) 88 (6) 81 (7)
Kendall’s W 0.37 0.73 0.39 0.75 0.57 0.64
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voting for a cross-sectional design no 2/3 majority for a
specific observational study design was reached.
The experts reasoned that in a cohort study the evolu-
tion of sequelae could be assessed; however, it would be
time-consuming and expensive. By comparison, a
case-control study as defined above addresses the rarity
and long latency of IMD and its corresponding sequelae,
allows comparison against healthy controls and covers a
variability of patients. Nevertheless, case-control studies
are prone to bias. Finally, a cross-sectional study can be
supplemented with retrospective data, would also allow
to include a control group, is easy to conduct, inexpen-
sive and therefore most practical. No concerns about
direction of causality were raised.
Discussion
IMD is an uncommon, but severe disease. MenC UMV
programs in Europe helped decrease the MenC related
disease burden. While MenB is still responsible for the ma-
jority of IMD cases in Europe, respective UMV programmes
are currently implemented less frequently in European
countries. Studies evaluating the cost-effectiveness of un-
common but severe diseases such as MenB are challenging
and draw on incomplete evidence on the actual disease bur-
den for this particular serogroup [8, 19].
Our results reinforce the need for a more detailed
examination of sequelae attributable to IMD and the dir-
ect long-term consequences for patients’ QoL as well as
the indirect impact onto their parents, siblings or
spouse. Experts argued that a detailed classification of
sequelae should distinguish both the severity of sequelae
and the impact of having multiple simultaneous seque-
lae. The experts’ perception of an unclear structure of
sequelae accords with the findings of a recent literature
review on this topic, which reports considerable hetero-
geneity in prevalence rates and inconsistent sampling
Table 4 Ranking results to Question 7
Age group 8–18 years > 18 years
Method Rank sum (group ranking) Rank sum (group ranking)
First round Second round First round Second round
Using an existing generic instrument 33 (1) 23 (1) 45 (1) 22 (1)
Using an existing disease-specific questionnaire 34 (2) 34 (2) 48 (2) 34 (2)
Direct preference elicitation using a Visual Analogue Scale 44 (3) 46 (3) 48 (2) 50 (3)
Using a Discrete Choice Experiment 59 (5) 63 (5) 60 (4) 59 (5)
Direct preference elicitation using the Time trade-off 74 (7) 81 (7) 64 (5) 83 (7)
Direct preference elicitation using the Standard Gamble 70 (6) 75 (6) 65 (6) 75 (6)
Develop a new disease specific questionnaire 49 (4) 50 (4) 66 (7) 56 (4)
Kendall’s W 0.23 0.49 0.07 0.50
Fig. 1 First and second round responses to Question 9. *The distinction between studies using the same or different sample(s) was not
considered during the 1st round
Marten et al. Health and Quality of Life Outcomes           (2019) 17:87 Page 6 of 9
strategies [16]. The experts emphasised that a valid oper-
ationalisation of the postulated classification is a
pre-requisite for a comprehensive QoL measurement.
Similarly, Viner et al. (2012) argued that the lack of reli-
able QoL data prevents the correct assessment of disease
burden associated with IMD [8].
On the other hand, the sought-after classification of
sequelae should also be pragmatic, since highly stratified
patient samples cannot be achieved in future prospective
studies due to the small number of patients worldwide
as well as the rarity of some sequelae. For example, in
2015 only 1682 prevalent serogroup B IMD cases were
reported in countries of the European Union [12].
Generally, the expert consensus on the remaining
questions of this DELPHI study suggests pragmatic and
goal-driven methods for future studies to overcome the
current lack of knowledge, which is impeding rational
decisions on the allocation of resources to vaccine devel-
opment and delivery. The experts acknowledged budget
and practical constraints in their answers, and therefore
preferred a single cross-sectional study. Further, it was
argued that a strategic sampling approach, targeting pa-
tients who contracted the disease at different times, as
well as the inclusion of a control group might help to
examine the evolution of sequelae and to assess QoL
losses. However, with respect to the study design we did
not achieve a 2/3 majority for a specific design; nonethe-
less, a tendency towards a retrospective data study with
a control group design was observed.
The preference for existing generic and disease-specific
QoL measures also reflects pragmatism. However, it
should be acknowledged that disease-specific QoL mea-
sures are problematic, since they usually do not allow
comparisons across different disease areas. They either
need to be preference-based or mapped onto a generic
preference-based measure in order to be comparable
across disease areas or to produce utilities for use in
cost-utility or modelling studies, which was desired by the
experts. Further, the choice of an appropriate QoL meas-
ure is constrained by decision-making bodies in several
countries, such as the National Institute for Health and
Care Excellence (NICE) in the United Kingdom [32].
Moreover, if the aim is to measure QoL across differ-
ent age groups, as it is necessary for IMD cases, the as-
sessment of health states along the transition to
adulthood is complicated. For this purpose, several
established and child-specific QoL measures were dis-
cussed. To date, standard paediatric QoL measures, such
as the EQ-5D-Y [33] or the Child Health Utility 9D
(CHU9D) [34], suffer from at least one of three key limi-
tations. First, validation for the youngest age group is
still pending; second, comparability with QoL question-
naires for adults is limited; and third, the scoring mecha-
nisms to translate the children’s answers into a utility
score might only be available from adult populations.
While the EQ-5D-Y does not offer a child specific value
set yet, the EQ-5D-Y broadens the applicable age range
(4 to 17 years) and enables the comparison with the in-
strument for adults by using the same descriptive sys-
tem. In this sense, the EQ-5D [35] could be applied, as
the instruments offer some methodological advantages
over other paediatric instruments [21].
Since IMD mainly affects children and adolescents,
negative spillover effects on family members and carers
must be considered in a comprehensive disease burden
study. Our results suggest that, as a practical matter,
these primarily need to be considered for the family net-
work and carers, i.e. the parents or siblings of patients
≤18 years. The expert panel agreed that the relevance of
the closest relatives and carer, i.e. the parents or the
spouse, spans all the included age groups and severity
levels. Our conclusion accords with findings from
Al-Janabi et al. (2016), who found the most impactful
health spillovers in close family members, but with a de-
clining rate with increasing social distance to the patient
[2]. Thus, the targeted group in a future IMD-related
QoL study should at least consist of patients and their
closest relatives and carer, irrespective of the severity of
sequelae and age of the patient.
Our DELPHI study of an expert panel with an inter-
national composition and multi-disciplinary experience
yielded robust results showing a high level of consensus
after the second round, reaching a moderate to strong
level of agreement on ranking tasks and a majority of 2/
3 in choice tasks, except for one question. The structure
of our study combined the advantages of anonymity in
the first round with the conveniences of a group discus-
sion prior to the second round, where all experts were
given the chance to elaborate on their opinion. Given
the often not observable or quantifiable differences in
the disease outcome between serogroups found in stud-
ies, the guidance from this study may help to improve
the understanding of the meningococcal disease burden
in general, but may also do so by emphasizing MenB to
detect potential differences in the disease outcome com-
pared to other serogroups. Several limitations of this
study should be acknowledged. Despite providing equal
opportunities during the discussion, we cannot rule out
that some arguments were prioritised over others. It is
inherent to the DELPHI technique that the results will
depend on the choice and composition of the expert
panel and on how the questions were framed. In this
sense, we note that the position of patient representa-
tives was slightly underrepresented numbers-wise. To
achieve appropriate framing of the questions, the ques-
tionnaire underwent quality control checks within the
study group. Finally, the individual expert views and the
degree of consensus among them could have changed
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between the time the DELPHI meeting took place and
the time the study was written and reviewed. A long-
term follow-up survey might be undertaken in some fu-
ture study.
Conclusion
A better conceptualisation of the structure of
IMD-specific sequelae and of how their diverse forms of
severity might impact the QoL of survivors of IMD as well
as their closest relatives and care-providers is needed to
generate reliable and generalisable data on QoL in the fu-
ture. The sought-after conceptualisation builds the basis
to overcome the general lack of reliable and relevant mea-
sures of the health burden attributable to serogroup B
IMD. However, the results of this DELPHI panel provide
useful guidance on how to choose the study design, target
population and appropriate QoL measures for future re-
search. This will help promote the consistency in study
methodology and sample characteristics.
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